I don't agree that epigenetics is losing its place in the science world. If that were the case I don't think Constellation would have fetched $1.7B USD. 

As far as Zenith going public, I hope that never happens as long as Don is at the helm. He has clearly shown he does not have what it takes to run a public company and I don't see him getting out of the way anytime soon. Zenith though has a lot of positive on the science side and Sanjay Lakhotia has a strong biotech business development background as well great pertinent education. Personally I hope Zenith gets sold lock stock and barrel soon. There seems to be a lot of potential in the current science programs, there are allegedly a number of promising other molecules and, despite the horrific stock price, the RVX preferreds may have a great deal of value at some point.